Stoke Therapeutics (STOK) Financials

$9.18 -0.18 (-1.92%)

Closing price 05/27/2025 04:00 PM Eastern

Extended Trading

$9.18 0.00 (0.00%)

As of 05/27/2025 07:01 PM Eastern

Annual Income Statements for Stoke Therapeutics

This table shows Stoke Therapeutics' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022
Period end date	12/31/2024	12/31/2023	12/31/2022
Net Income / (Loss) Attributable to Common Shareholders	-89	-105	-101
Consolidated Net Income / (Loss)	-89	-105	-101
Net Income / (Loss) Continuing Operations	-89	-105	-101
Total Pre-Tax Income	-89	-105	-101
Total Operating Income	-101	-115	-104
Total Gross Profit	37	8.78	12
Total Revenue	37	8.78	12
Operating Revenue	37	8.78	12
Total Cost of Revenue	0.00	0.00	0.00
Total Operating Expenses	138	124	117
Selling, General & Admin Expense	49	41	39
Research & Development Expense	89	82	78
Total Other Income / (Expense), net	12	10	3.29
Interest & Investment Income	13	9.91	3.12
Other Income / (Expense), net	-0.25	0.17	0.17
Basic Earnings per Share	($1.65)	($2.38)	($2.60)
Weighted Average Basic Shares Outstanding	54.01M	43.99M	38.90M
Diluted Earnings per Share	($1.65)	($2.38)	($2.60)
Weighted Average Diluted Shares Outstanding	54.01M	43.99M	38.90M
Weighted Average Basic & Diluted Shares Outstanding	54.08M	46.30M	44.15M

This table shows Stoke Therapeutics' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Period end date	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022
Net Income / (Loss) Attributable to Common Shareholders	-11	-26	-26	-26	-27	-24	-30	-23	-25	-26
Consolidated Net Income / (Loss)	-10	-26	-26	-26	-27	-25	-31	-23	-26	-26
Net Income / (Loss) Continuing Operations	-10	-26	-26	-26	-27	-25	-31	-23	-26	-26
Total Pre-Tax Income	-10	-26	-26	-26	-27	-25	-31	-23	-26	-26
Total Operating Income	-14	-30	-29	-28	-30	-27	-33	-25	-27	-27
Total Gross Profit	23	4.89	4.83	4.22	2.80	3.31	-2.48	5.15	3.27	2.91
Total Revenue	23	4.89	4.83	4.22	2.80	3.31	-2.48	5.15	3.27	2.91
Operating Revenue	23	4.89	4.83	4.22	2.80	3.31	-2.48	5.15	-	-
Total Operating Expenses	36	35	34	33	32	31	31	30	30	30
Selling, General & Admin Expense	13	13	13	10	11	10	10	10	9.38	9.94
Research & Development Expense	23	22	21	22	22	20	21	20	21	20
Total Other Income / (Expense), net	3.17	3.57	3.65	2.00	2.63	2.69	2.61	2.15	1.52	1.04
Interest & Investment Income	2.97	3.55	3.70	2.43	2.59	2.65	2.57	2.10	1.48	1.00
Other Income / (Expense), net	0.20	0.03	-0.05	-0.43	0.04	0.04	0.04	0.04	0.04	0.04
Basic Earnings per Share	($0.15)	($0.47)	($0.46)	($0.57)	($0.61)	($0.55)	($0.69)	($0.53)	($0.65)	($0.66)
Weighted Average Basic Shares Outstanding	54.01M	56.34M	55.77M	46.25M	43.99M	44.27M	44.19M	42.54M	38.90M	39.42M
Diluted Earnings per Share	($0.15)	($0.47)	($0.46)	($0.57)	($0.61)	($0.55)	($0.69)	($0.53)	($0.65)	($0.66)
Weighted Average Diluted Shares Outstanding	54.01M	56.34M	55.77M	46.25M	43.99M	44.27M	44.19M	42.54M	38.90M	39.42M
Weighted Average Basic & Diluted Shares Outstanding	54.08M	52.97M	52.65M	52.12M	46.30M	44.65M	44.26M	44.19M	44.15M	39.43M

This table details how cash moves in and out of Stoke Therapeutics' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022
Period end date	12/31/2024	12/31/2023	12/31/2022
Net Change in Cash & Equivalents	-63	78	-31
Net Cash From Operating Activities	-87	-81	-32
Net Cash From Continuing Operating Activities	-87	-81	-32
Net Income / (Loss) Continuing Operations	-89	-105	-101
Consolidated Net Income / (Loss)	-89	-105	-101
Depreciation Expense	2.18	2.47	1.55
Amortization Expense	-1.64	-0.33	-0.21
Non-Cash Adjustments To Reconcile Net Income	30	28	25
Changes in Operating Assets and Liabilities, net	-28	-6.03	43
Net Cash From Investing Activities	-107	106	-46
Net Cash From Continuing Investing Activities	-107	106	-46
Purchase of Property, Plant & Equipment	-0.20	-1.62	-3.96
Purchase of Investments	-167	0.00	-201
Sale and/or Maturity of Investments	60	108	159
Net Cash From Financing Activities	131	53	46
Net Cash From Continuing Financing Activities	131	53	46
Issuance of Common Equity	9.49	53	46
Other Financing Activities, net	122	0.37	0.49

This table details how cash moves in and out of Stoke Therapeutics' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Period end date	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022
Net Change in Cash & Equivalents	-22	-43	15	-13	1.47	-2.08	1.72	77	0.16	46
Net Cash From Operating Activities	-23	-22	-17	-25	-21	-17	-22	-21	-22	-22
Net Cash From Continuing Operating Activities	-23	-22	-17	-25	-21	-17	-22	-21	-22	-22
Net Income / (Loss) Continuing Operations	-10	-26	-26	-26	-27	-25	-31	-23	-26	-26
Consolidated Net Income / (Loss)	-10	-26	-26	-26	-27	-25	-31	-23	-26	-26
Depreciation Expense	0.53	0.54	0.55	0.56	0.62	0.64	0.61	0.60	0.61	0.39
Amortization Expense	-0.78	-0.55	-0.29	-0.02	-0.09	-0.12	-0.15	0.03	-0.15	-0.10
Non-Cash Adjustments To Reconcile Net Income	7.72	8.07	7.99	5.96	6.65	7.12	7.32	6.44	6.33	6.46
Changes in Operating Assets and Liabilities, net	-20	-3.24	-0.03	-4.69	-0.88	-0.35	1.07	-5.88	-3.51	-2.69
Net Cash From Investing Activities	0.82	-30	-88	9.99	15	15	23	53	22	67
Net Cash From Continuing Investing Activities	0.82	-30	-88	9.99	15	15	23	53	22	67
Purchase of Property, Plant & Equipment	-0.04	-0.10	-0.05	-0.01	-0.23	-0.38	-0.84	-0.17	-0.41	-2.03
Purchase of Investments	-29	-50	-	-	-	-	-	-	4.87	-9.71
Sale and/or Maturity of Investments	30	20	-	10	15	15	24	53	18	79
Net Cash From Financing Activities	0.57	8.16	121	1.72	7.34	0.56	0.05	45	0.04	0.43
Net Cash From Continuing Financing Activities	0.57	8.16	121	1.72	7.34	0.56	0.05	45	0.04	0.43
Issuance of Common Equity	0.00	8.02	-	1.47	7.34	0.35	45	0.15	-	46
Other Financing Activities, net	0.57	0.14	121	0.25	0.00	0.21	-45	45	0.04	-45

This table presents Stoke Therapeutics' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022
Period end date	12/31/2024	12/31/2023	12/31/2022
Total Assets	272	228	256
Total Current Assets	233	215	244
Cash & Equivalents	128	191	114
Restricted Cash	0.08	0.00	-
Short-Term Investments	89	9.95	116
Note & Lease Receivable	0.70	0.06	0.59
Prepaid Expenses	11	11	11
Other Current Assets	3.97	2.56	2.96
Plant, Property, & Equipment, net	3.91	5.82	6.68
Total Noncurrent Assets	35	7.18	5.32
Long-Term Investments	30	0.00	-
Other Noncurrent Operating Assets	5.07	7.18	5.32
Total Liabilities & Shareholders' Equity	272	228	256
Total Liabilities	43	69	71
Total Current Liabilities	40	31	31
Accounts Payable	2.50	1.70	0.77
Accrued Expenses	19	14	16
Current Deferred Revenue	19	15	15
Total Noncurrent Liabilities	2.48	38	40
Noncurrent Deferred Revenue	0.00	33	37
Other Noncurrent Operating Liabilities	2.48	4.88	2.97
Commitments & Contingencies	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	229	160	185
Total Preferred & Common Equity	229	160	185
Total Common Equity	229	160	185
Common Stock	720	561	483
Retained Earnings	-491	-402	-297
Accumulated Other Comprehensive Income / (Loss)	-0.15	-0.02	-1.18

This table presents Stoke Therapeutics' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric	Q3 2024	Q2 2024	Q1 2024	Q3 2023	Q2 2023	Q1 2023	Q3 2022
Period end date	9/30/2024	6/30/2024	3/31/2024	9/30/2023	6/30/2023	3/31/2023	9/30/2022
Total Assets	293	308	205	240	257	282	278
Total Current Assets	254	297	193	230	246	270	265
Cash & Equivalents	150	193	179	190	192	190	113
Restricted Cash	0.08	0.08	-	-	-	-	0.57
Short-Term Investments	89	89	0.00	25	39	63	138
Note & Lease Receivable	0.69	0.31	0.01	0.10	0.14	0.49	0.40
Prepaid Expenses	9.84	10	11	11	11	10	13
Other Current Assets	3.81	4.29	3.96	4.27	3.70	5.88	0.00
Plant, Property, & Equipment, net	4.33	4.77	5.28	6.22	6.47	6.79	7.16
Total Noncurrent Assets	35	5.99	6.63	3.65	4.22	4.77	5.30
Long-Term Investments	30	-	-	-	-	-	-
Other Noncurrent Operating Assets	5.42	5.99	6.63	3.65	4.22	4.77	5.30
Total Liabilities & Shareholders' Equity	293	308	205	240	257	282	278
Total Liabilities	61	65	65	67	67	68	73
Total Current Liabilities	50	44	36	25	22	32	29
Accounts Payable	2.49	3.95	2.10	3.08	1.56	4.30	1.91
Accrued Expenses	16	15	13	13	12	14	14
Current Deferred Revenue	32	26	21	8.74	8.06	13	13
Total Noncurrent Liabilities	11	21	29	42	45	36	45
Noncurrent Deferred Revenue	8.29	17	25	41	43	34	41
Other Noncurrent Operating Liabilities	3.05	3.61	4.21	0.96	1.63	2.30	3.61
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	232	243	140	173	190	214	204
Total Preferred & Common Equity	232	243	140	173	190	214	204
Total Common Equity	232	243	140	173	190	214	204
Common Stock	712	697	569	548	541	534	477
Retained Earnings	-480	-454	-428	-375	-350	-320	-271
Accumulated Other Comprehensive Income / (Loss)	0.17	-0.02	0.00	-0.15	-0.38	-0.60	-1.70

This table displays calculated financial ratios and metrics derived from Stoke Therapeutics' official financial filings.

Metric	2024	2023	2022
Period end date	12/31/2024	12/31/2023	12/31/2022
Growth Metrics	-	-	-
Revenue Growth	316.34%	-29.22%	0.00%
EBITDA Growth	10.12%	-9.34%	-21.28%
EBIT Growth	11.33%	-10.00%	-21.26%
NOPAT Growth	11.68%	-9.98%	-21.25%
Net Income Growth	15.01%	-3.59%	-17.79%
EPS Growth	30.67%	8.46%	-11.11%
Operating Cash Flow Growth	-7.13%	-154.40%	52.37%
Free Cash Flow Firm Growth	-14.12%	-174.45%	48.97%
Invested Capital Growth	57.50%	6.52%	-2,100.98%
Revenue Q/Q Growth	118.34%	-5.06%	35.78%
EBITDA Q/Q Growth	13.15%	-2.12%	-2.47%
EBIT Q/Q Growth	13.67%	-2.15%	-2.61%
NOPAT Q/Q Growth	13.58%	-2.15%	-2.60%
Net Income Q/Q Growth	15.62%	-1.26%	-1.21%
EPS Q/Q Growth	21.80%	1.65%	1.14%
Operating Cash Flow Q/Q Growth	-3.02%	2.08%	-23.75%
Free Cash Flow Firm Q/Q Growth	-9.57%	2.07%	-38.50%
Invested Capital Q/Q Growth	52.10%	-0.26%	6.94%
Profitability Metrics	-	-	-
Gross Margin	100.00%	100.00%	100.00%
EBITDA Margin	-276.53%	-1,280.90%	-829.13%
Operating Margin	-277.31%	-1,307.21%	-841.24%
EBIT Margin	-277.99%	-1,305.32%	-839.90%
Profit (Net Income) Margin	-243.42%	-1,192.47%	-814.73%
Tax Burden Percent	100.00%	100.00%	100.00%
Interest Burden Percent	87.56%	91.35%	97.00%
Effective Tax Rate	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	0.00%	0.00%	0.00%
ROIC Less NNEP Spread (ROIC-NNEP)	0.00%	0.00%	0.00%
Return on Net Nonoperating Assets (RNNOA)	0.00%	0.00%	0.00%
Return on Equity (ROE)	-45.80%	-60.80%	-50.20%
Cash Return on Invested Capital (CROIC)	0.00%	0.00%	0.00%
Operating Return on Assets (OROA)	-40.66%	-47.32%	-42.10%
Return on Assets (ROA)	-35.60%	-43.23%	-40.84%
Return on Common Equity (ROCE)	-45.80%	-60.80%	-50.20%
Return on Equity Simple (ROE_SIMPLE)	-38.85%	-65.62%	-54.68%
Net Operating Profit after Tax (NOPAT)	-71	-80	-73
NOPAT Margin	-194.12%	-915.05%	-588.87%
Net Nonoperating Expense Percent (NNEP)	-8.04%	-11.30%	-12.47%
Return On Investment Capital (ROIC_SIMPLE)	-30.98%	-50.35%	-
Cost of Revenue to Revenue	0.00%	0.00%	0.00%
SG&A Expenses to Revenue	133.48%	470.64%	313.78%
R&D to Revenue	243.83%	936.57%	627.46%
Operating Expenses to Revenue	377.31%	1,407.21%	941.24%
Earnings before Interest and Taxes (EBIT)	-102	-115	-104
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-101	-112	-103
Valuation Ratios	-	-	-
Price to Book Value (P/BV)	2.55	1.47	1.97
Price to Tangible Book Value (P/TBV)	2.55	1.47	1.97
Price to Revenue (P/Rev)	15.98	26.75	29.34
Price to Earnings (P/E)	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	0.00	0.00	0.00
Enterprise Value to Revenue (EV/Rev)	9.23	3.81	10.83
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00
Leverage & Solvency	-	-	-
Debt to Equity	0.00	0.00	0.00
Long-Term Debt to Equity	0.00	0.00	0.00
Financial Leverage	-1.15	-1.25	-1.12
Leverage Ratio	1.29	1.41	1.23
Compound Leverage Factor	1.13	1.28	1.19
Debt to Total Capital	0.00%	0.00%	0.00%
Short-Term Debt to Total Capital	0.00%	0.00%	0.00%
Long-Term Debt to Total Capital	0.00%	0.00%	0.00%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%
Common Equity to Total Capital	100.00%	100.00%	100.00%
Debt to EBITDA	0.00	0.00	0.00
Net Debt to EBITDA	0.00	0.00	0.00
Long-Term Debt to EBITDA	0.00	0.00	0.00
Debt to NOPAT	0.00	0.00	0.00
Net Debt to NOPAT	0.00	0.00	0.00
Long-Term Debt to NOPAT	0.00	0.00	0.00
Altman Z-Score	5.46	-1.06	1.14
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-
Current Ratio	5.81	6.99	7.77
Quick Ratio	5.43	6.54	7.33
Cash Flow Metrics	-	-	-
Free Cash Flow to Firm (FCFF)	-95	-83	-30
Operating Cash Flow to CapEx	-42,783.74%	-5,016.52%	-804.29%
Free Cash Flow to Firm to Interest Expense	0.00	0.00	0.00
Operating Cash Flow to Interest Expense	0.00	0.00	0.00
Operating Cash Flow Less CapEx to Interest Expense	0.00	0.00	0.00
Efficiency Ratios	-	-	-
Asset Turnover	0.15	0.04	0.05
Accounts Receivable Turnover	0.00	0.00	0.00
Inventory Turnover	0.00	0.00	0.00
Fixed Asset Turnover	7.51	1.41	2.29
Accounts Payable Turnover	0.00	0.00	0.00
Days Sales Outstanding (DSO)	0.00	0.00	0.00
Days Inventory Outstanding (DIO)	0.00	0.00	0.00
Days Payable Outstanding (DPO)	0.00	0.00	0.00
Cash Conversion Cycle (CCC)	0.00	0.00	0.00
Capital & Investment Metrics	-	-	-
Invested Capital	-18	-42	-45
Invested Capital Turnover	-1.23	-0.20	-0.53
Increase / (Decrease) in Invested Capital	24	2.92	-43
Enterprise Value (EV)	337	33	134
Market Capitalization	584	235	364
Book Value per Share	$4.32	$3.57	$4.69
Tangible Book Value per Share	$4.32	$3.57	$4.69
Total Capital	229	160	185
Total Debt	0.00	0.00	0.00
Total Long-Term Debt	0.00	0.00	0.00
Net Debt	-247	-201	-230
Capital Expenditures (CapEx)	0.20	1.62	3.96
Debt-free, Cash-free Net Working Capital (DFCFNWC)	-24	-17	-17
Debt-free Net Working Capital (DFNWC)	193	185	213
Net Working Capital (NWC)	193	185	213
Net Nonoperating Expense (NNE)	18	24	28
Net Nonoperating Obligations (NNO)	-247	-201	-230
Total Depreciation and Amortization (D&A)	0.54	2.14	1.34
Debt-free, Cash-free Net Working Capital to Revenue	-66.40%	-192.19%	-136.39%
Debt-free Net Working Capital to Revenue	527.15%	2,101.59%	1,714.44%
Net Working Capital to Revenue	527.15%	2,101.59%	1,714.44%
Earnings Adjustments	-	-	-
Adjusted Basic Earnings per Share	($1.65)	($2.38)	($2.60)
Adjusted Weighted Average Basic Shares Outstanding	54.01M	43.99M	38.90M
Adjusted Diluted Earnings per Share	($1.65)	($2.38)	($2.60)
Adjusted Weighted Average Diluted Shares Outstanding	54.01M	43.99M	38.90M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	54.08M	46.30M	44.15M
Normalized Net Operating Profit after Tax (NOPAT)	-71	-80	-73
Normalized NOPAT Margin	-194.12%	-915.05%	-588.87%
Pre Tax Income Margin	-243.42%	-1,192.47%	-814.73%
Debt Service Ratios	-	-	-
EBIT to Interest Expense	0.00	0.00	0.00
NOPAT to Interest Expense	0.00	0.00	0.00
EBIT Less CapEx to Interest Expense	0.00	0.00	0.00
NOPAT Less CapEx to Interest Expense	0.00	0.00	0.00
Payout Ratios	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.00%	0.00%

This table displays calculated financial ratios and metrics derived from Stoke Therapeutics' official financial filings.

Metric	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Period end date	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022
Growth Metrics	-	-	-	-	-	-	-	-	-	-
Revenue Growth	707.35%	47.94%	294.72%	-18.17%	-14.32%	13.87%	-176.79%	71.73%	0.00%	0.00%
EBITDA Growth	52.74%	-12.38%	11.07%	-17.66%	-8.75%	0.53%	-30.57%	1.04%	-10.27%	-20.06%
EBIT Growth	54.46%	-10.23%	11.53%	-16.85%	-8.89%	-0.32%	-31.85%	0.42%	-10.82%	-19.72%
NOPAT Growth	53.85%	-10.17%	11.79%	-14.91%	-8.88%	-0.32%	-31.79%	0.42%	-10.80%	-19.68%
Net Income Growth	61.12%	-7.69%	16.18%	-16.98%	-5.08%	6.01%	-24.35%	8.54%	-4.94%	-15.55%
EPS Growth	75.41%	14.55%	33.33%	-7.55%	6.15%	16.67%	-9.52%	19.70%	4.41%	-10.00%
Operating Cash Flow Growth	-12.32%	-25.22%	19.83%	-15.03%	7.71%	21.74%	-9.39%	-165.73%	-37.61%	-50.22%
Free Cash Flow Firm Growth	-42.25%	-0.71%	33.81%	29.99%	-199.74%	-183.95%	-189.45%	-175.38%	244.76%	289.13%
Invested Capital Growth	57.50%	11.04%	4.62%	4.05%	6.52%	13.23%	20.48%	25.15%	-2,100.98%	-4,073.64%
Revenue Q/Q Growth	362.08%	1.30%	14.59%	50.52%	-15.33%	233.33%	-148.16%	57.60%	12.53%	-10.09%
EBITDA Q/Q Growth	54.27%	-2.92%	-3.08%	2.58%	-8.74%	18.56%	-36.38%	9.96%	0.54%	-6.91%
EBIT Q/Q Growth	55.12%	-1.99%	-2.05%	2.52%	-8.65%	18.15%	-34.78%	9.16%	-0.10%	-7.58%
NOPAT Q/Q Growth	54.49%	-2.25%	-3.42%	4.11%	-8.64%	18.12%	-34.72%	9.14%	-0.10%	-7.57%
Net Income Q/Q Growth	60.34%	-2.86%	2.57%	2.17%	-9.84%	19.94%	-35.97%	12.12%	1.75%	-5.92%
EPS Q/Q Growth	68.09%	-2.17%	19.30%	6.56%	-10.91%	20.29%	-30.19%	18.46%	1.52%	-4.76%
Operating Cash Flow Q/Q Growth	-7.30%	-23.68%	28.86%	-18.97%	-19.62%	20.82%	-2.08%	4.55%	-1.44%	-10.68%
Free Cash Flow Firm Q/Q Growth	-31.25%	-14.10%	-4.52%	9.12%	7.07%	25.02%	-10.56%	-229.47%	-21.78%	-20.10%
Invested Capital Q/Q Growth	52.10%	5.68%	-2.90%	8.58%	-0.26%	-1.13%	-3.52%	10.94%	6.94%	7.32%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-
Gross Margin	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	0.00%	100.00%	100.00%	100.00%
EBITDA Margin	-60.63%	-612.63%	-603.00%	-670.33%	-1,035.70%	-806.47%	0.00%	-466.21%	-816.03%	-923.24%
Operating Margin	-60.38%	-613.06%	-607.37%	-672.96%	-1,056.30%	-823.28%	0.00%	-479.23%	-831.29%	-934.53%
EBIT Margin	-59.49%	-612.48%	-608.36%	-683.11%	-1,054.80%	-822.04%	0.00%	-478.42%	-830.04%	-933.08%
Profit (Net Income) Margin	-46.35%	-540.05%	-531.88%	-625.57%	-962.44%	-741.90%	0.00%	-437.60%	-784.80%	-898.83%
Tax Burden Percent	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%
Interest Burden Percent	77.91%	88.17%	87.43%	91.58%	91.24%	90.25%	92.27%	91.47%	94.55%	96.33%
Effective Tax Rate	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
ROIC Less NNEP Spread (ROIC-NNEP)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Net Nonoperating Assets (RNNOA)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Equity (ROE)	-45.80%	-52.06%	-47.85%	-61.29%	-60.80%	-54.83%	-50.64%	-43.62%	-50.20%	-45.22%
Cash Return on Invested Capital (CROIC)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Operating Return on Assets (OROA)	-8.70%	-38.46%	-32.66%	-22.01%	-38.24%	-29.38%	0.00%	-23.30%	-41.61%	-32.08%
Return on Assets (ROA)	-6.78%	-33.91%	-28.55%	-20.15%	-34.89%	-26.52%	0.00%	-21.31%	-39.34%	-30.91%
Return on Common Equity (ROCE)	-45.80%	-52.06%	-47.85%	-61.29%	-60.80%	-54.83%	-50.64%	-43.62%	-50.20%	-45.22%
Return on Equity Simple (ROE_SIMPLE)	0.00%	-45.43%	-42.67%	-77.33%	0.00%	-59.77%	-55.19%	-46.28%	0.00%	-48.92%
Net Operating Profit after Tax (NOPAT)	-9.56	-21	-21	-20	-21	-19	-23	-17	-19	-19
NOPAT Margin	-42.27%	-429.14%	-425.16%	-471.07%	-739.41%	-576.29%	0.00%	-335.46%	-581.91%	-654.17%
Net Nonoperating Expense Percent (NNEP)	-0.41%	-2.24%	-2.01%	-3.01%	-2.90%	-2.35%	-2.90%	-1.92%	-2.95%	-2.91%
Return On Investment Capital (ROIC_SIMPLE)	-4.17%	-	-	-	-12.98%	-	-	-	-	-
Cost of Revenue to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
SG&A Expenses to Revenue	56.80%	259.34%	269.86%	242.41%	378.79%	310.49%	0.00%	198.19%	287.03%	342.31%
R&D to Revenue	103.58%	453.72%	437.51%	530.55%	777.51%	612.79%	0.00%	381.04%	644.26%	692.22%
Operating Expenses to Revenue	160.38%	713.06%	707.37%	772.96%	1,156.30%	923.28%	0.00%	579.23%	931.29%	1,034.53%
Earnings before Interest and Taxes (EBIT)	-13	-30	-29	-29	-30	-27	-33	-25	-27	-27
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-14	-30	-29	-28	-29	-27	-33	-24	-27	-27
Valuation Ratios	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	2.55	2.79	2.90	4.45	1.47	1.01	2.47	1.72	1.97	2.48
Price to Tangible Book Value (P/TBV)	2.55	2.79	2.90	4.45	1.47	1.01	2.47	1.72	1.97	2.48
Price to Revenue (P/Rev)	15.98	38.65	46.46	79.69	26.75	18.86	53.11	25.26	29.34	55.40
Price to Earnings (P/E)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Revenue (EV/Rev)	9.23	22.57	27.85	56.93	3.81	0.00	26.94	7.84	10.83	27.79
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-
Debt to Equity	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to Equity	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Financial Leverage	-1.15	-1.19	-1.19	-1.22	-1.25	-1.24	-1.22	-1.21	-1.12	-1.11
Leverage Ratio	1.29	1.32	1.30	1.38	1.41	1.37	1.35	1.32	1.23	1.20
Compound Leverage Factor	1.00	1.16	1.14	1.26	1.28	1.24	1.24	1.20	1.16	1.16
Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Short-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Long-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%
Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Altman Z-Score	6.53	4.60	5.15	3.36	0.17	0.07	2.97	2.44	2.14	3.49
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-
Current Ratio	5.81	5.09	6.67	5.43	6.99	9.13	11.28	8.57	7.77	9.19
Quick Ratio	5.43	4.81	6.34	5.02	6.54	8.52	10.61	8.06	7.33	8.75
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	-34	-26	-22	-21	-24	-25	-34	-31	24	30
Operating Cash Flow to CapEx	-55,221.43%	-20,985.44%	-37,993.48%	-204,716.67%	-9,017.03%	-4,507.05%	-2,598.33%	-12,943.03%	-5,470.17%	-1,086.50%
Free Cash Flow to Firm to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.15	0.06	0.05	0.03	0.04	0.04	0.03	0.05	0.05	0.03
Accounts Receivable Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Inventory Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Fixed Asset Turnover	7.51	3.17	2.70	1.30	1.41	1.38	1.43	2.46	2.29	1.81
Accounts Payable Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Sales Outstanding (DSO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Inventory Outstanding (DIO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Payable Outstanding (DPO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Cash Conversion Cycle (CCC)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-
Invested Capital	-18	-37	-39	-38	-42	-42	-41	-40	-45	-48
Invested Capital Turnover	-1.23	-0.42	-0.38	-0.20	-0.20	-0.21	-0.19	-0.31	-0.53	-0.39
Increase / (Decrease) in Invested Capital	24	4.61	1.90	1.61	2.92	6.36	11	13	-43	-49
Enterprise Value (EV)	337	378	422	447	33	-40	238	114	134	254
Market Capitalization	584	647	704	625	235	174	470	368	364	506
Book Value per Share	$4.32	$4.41	$4.66	$3.03	$3.57	$3.91	$4.30	$4.84	$4.69	$5.18
Tangible Book Value per Share	$4.32	$4.41	$4.66	$3.03	$3.57	$3.91	$4.30	$4.84	$4.69	$5.18
Total Capital	229	232	243	140	160	173	190	214	185	204
Total Debt	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Long-Term Debt	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt	-247	-269	-282	-179	-201	-215	-231	-254	-230	-252
Capital Expenditures (CapEx)	0.04	0.10	0.05	0.01	0.23	0.38	0.84	0.17	0.41	2.03
Debt-free, Cash-free Net Working Capital (DFCFNWC)	-24	-36	-30	-21	-17	-9.90	-7.05	-15	-17	-16
Debt-free Net Working Capital (DFNWC)	193	204	252	158	185	205	224	239	213	236
Net Working Capital (NWC)	193	204	252	158	185	205	224	239	213	236
Net Nonoperating Expense (NNE)	0.92	5.43	5.16	6.51	6.25	5.48	7.37	5.26	6.63	7.11
Net Nonoperating Obligations (NNO)	-247	-269	-282	-179	-201	-215	-231	-254	-230	-252
Total Depreciation and Amortization (D&A)	-0.26	-0.01	0.26	0.54	0.54	0.52	0.47	0.63	0.46	0.29
Debt-free, Cash-free Net Working Capital to Revenue	-66.40%	-212.21%	-195.03%	-266.39%	-192.19%	-107.05%	-79.73%	-102.80%	-136.39%	-179.71%
Debt-free Net Working Capital to Revenue	527.15%	1,216.98%	1,665.99%	2,010.26%	2,101.59%	2,214.73%	2,536.97%	1,639.82%	1,714.44%	2,581.06%
Net Working Capital to Revenue	527.15%	1,216.98%	1,665.99%	2,010.26%	2,101.59%	2,214.73%	2,536.97%	1,639.82%	1,714.44%	2,581.06%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	($0.15)	($0.47)	($0.46)	($0.57)	($0.61)	($0.55)	($0.69)	($0.53)	($0.65)	($0.66)
Adjusted Weighted Average Basic Shares Outstanding	54.01M	56.34M	55.77M	46.25M	43.99M	44.27M	44.19M	42.54M	38.90M	39.42M
Adjusted Diluted Earnings per Share	($0.15)	($0.47)	($0.46)	($0.57)	($0.61)	($0.55)	($0.69)	($0.53)	($0.65)	($0.63)
Adjusted Weighted Average Diluted Shares Outstanding	54.01M	56.34M	55.77M	46.25M	43.99M	44.27M	44.19M	42.54M	38.90M	39.26M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	54.08M	52.97M	52.65M	52.12M	46.30M	44.65M	44.26M	44.19M	44.15M	39.43M
Normalized Net Operating Profit after Tax (NOPAT)	-9.56	-21	-21	-20	-21	-19	-23	-17	-19	-19
Normalized NOPAT Margin	-42.27%	-429.14%	-425.16%	-471.07%	-739.41%	-576.29%	0.00%	-335.46%	-581.91%	-654.17%
Pre Tax Income Margin	-46.35%	-540.05%	-531.88%	-625.57%	-962.44%	-741.90%	0.00%	-437.60%	-784.80%	-898.83%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
NOPAT to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
EBIT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
NOPAT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Payout Ratios	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

Frequently Asked Questions About Stoke Therapeutics' Financials

When does Stoke Therapeutics's financial year end?

According to the most recent income statement we have on file, Stoke Therapeutics' fiscal year ends in December. Their fiscal year 2024 ended on December 31, 2024.

How has Stoke Therapeutics' net income changed over the last 2 years?

Stoke Therapeutics' net income appears to be on a downward trend, with a most recent value of -$88.98 million in 2024, falling from -$101.07 million in 2022. The previous period was -$104.70 million in 2023. Check out Stoke Therapeutics' forecast to explore projected trends and price targets.

What is Stoke Therapeutics's operating income?

Stoke Therapeutics's total operating income in 2024 was -$101.37 million, based on the following breakdown:

Total Gross Profit: $36.56 million
Total Operating Expenses: $137.93 million

How has Stoke Therapeutics revenue changed over the last 2 years?

Over the last 2 years, Stoke Therapeutics' total revenue changed from $12.41 million in 2022 to $36.56 million in 2024, a change of 194.7%.

How much debt does Stoke Therapeutics have?

Stoke Therapeutics' total liabilities were at $42.53 million at the end of 2024, a 38.2% decrease from 2023, and a 40.3% decrease since 2022.

How much cash does Stoke Therapeutics have?

In the past 2 years, Stoke Therapeutics' cash and equivalents has ranged from $113.56 million in 2022 to $191.44 million in 2023, and is currently $127.98 million as of their latest financial filing in 2024.

How has Stoke Therapeutics' book value per share changed over the last 2 years?

Over the last 2 years, Stoke Therapeutics' book value per share changed from 4.69 in 2022 to 4.32 in 2024, a change of -7.8%.

Related Companies

This page (NASDAQ:STOK) was last updated on 5/28/2025 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Stoke Therapeutics (STOK) Financials

Frequently Asked Questions About Stoke Therapeutics' Financials

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Stoke Therapeutics (STOK) Financials

Annual Income Statements for Stoke Therapeutics

Quarterly Income Statements for Stoke Therapeutics

Annual Cash Flow Statements for Stoke Therapeutics

Quarterly Cash Flow Statements for Stoke Therapeutics

Annual Balance Sheets for Stoke Therapeutics

Quarterly Balance Sheets for Stoke Therapeutics

Annual Metrics And Ratios for Stoke Therapeutics

Quarterly Metrics And Ratios for Stoke Therapeutics

Frequently Asked Questions About Stoke Therapeutics' Financials

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools